0000899243-20-017758.txt : 20200626
0000899243-20-017758.hdr.sgml : 20200626
20200626161521
ACCESSION NUMBER: 0000899243-20-017758
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200625
FILED AS OF DATE: 20200626
DATE AS OF CHANGE: 20200626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gould Robert J
CENTRAL INDEX KEY: 0001577034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 20994299
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-25
0
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001577034
Gould Robert J
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
1
1
0
0
See Remarks
Common Stock
2020-06-25
4
S
0
2500
20.7968
D
537345
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $21.26, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
President & Chief Executive Officer
/s/ Peter Thomson, as attorney-in-fact for Robert J. Gould
2020-06-26